Globus Medical Future Growth
Future criteria checks 4/6
Globus Medical is forecast to grow earnings and revenue by 40.9% and 11.2% per annum respectively. EPS is expected to grow by 39.9% per annum. Return on equity is forecast to be 10.2% in 3 years.
Key information
40.9%
Earnings growth rate
39.9%
EPS growth rate
| Medical Equipment earnings growth | 16.6% |
| Revenue growth rate | 11.2% |
| Future return on equity | 10.2% |
| Analyst coverage | Good |
| Last updated | 21 May 2024 |
Recent future growth updates
Recent updates
An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued
Apr 08
Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly
Mar 20Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock
Feb 27Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?
Feb 09Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings
Jan 17Globus Medical: Merger Overhang Lingering
Nov 27Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?
Nov 14Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?
Oct 27Globus Medical: Almost Having My Back
Sep 13Globus Medical: Slightly Too Pricey Right Now
Aug 07Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy
Jul 18Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?
Jul 11Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching
Jun 18Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around
Apr 09What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?
Mar 22Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?
Feb 24Globus Medical Q4 2022 Earnings Preview
Feb 20Globus Medical: An Impressive Long-Term Revenue Growth Play
Jan 08Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?
Dec 22Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends
Dec 01Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line
Nov 08A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)
Oct 15Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact
Sep 02Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around
Sep 02Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?
Aug 11Globus Medical: Low Rates Sensitivity, Seeking 26% Return Objective
Jun 05Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital
May 24Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?
May 06An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 22% Undervalued
Mar 14Globus Medical Continues To Flex Its Innovation Muscles To Drive Share Growth
Mar 01Globus Medical's (NYSE:GMED) Performance Is Even Better Than Its Earnings Suggest
Feb 24Returns On Capital At Globus Medical (NYSE:GMED) Paint A Concerning Picture
Feb 08Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?
Jan 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,853 | 456 | N/A | N/A | 10 |
| 12/31/2025 | 2,654 | 382 | 750 | N/A | 14 |
| 12/31/2024 | 2,475 | 227 | 908 | N/A | 14 |
| 3/31/2024 | 1,898 | 67 | 152 | 243 | N/A |
| 12/31/2023 | 1,568 | 123 | 165 | 243 | N/A |
| 9/30/2023 | 1,226 | 158 | 129 | 203 | N/A |
| 6/30/2023 | 1,097 | 204 | 121 | 185 | N/A |
| 3/31/2023 | 1,069 | 201 | 117 | 187 | N/A |
| 12/31/2022 | 1,023 | 190 | 104 | 178 | N/A |
| 9/30/2022 | 998 | 155 | 118 | 191 | N/A |
| 6/30/2022 | 974 | 155 | 157 | 235 | N/A |
| 3/31/2022 | 961 | 142 | 194 | 257 | N/A |
| 12/31/2021 | 958 | 149 | 219 | 276 | N/A |
| 9/30/2021 | 942 | 187 | 226 | 280 | N/A |
| 6/30/2021 | 928 | 184 | 203 | 256 | N/A |
| 3/31/2021 | 826 | 122 | 165 | 220 | N/A |
| 12/31/2020 | 789 | 102 | 135 | 199 | N/A |
| 9/30/2020 | 767 | 95 | 108 | 173 | N/A |
| 6/30/2020 | 747 | 89 | 115 | 176 | N/A |
| 3/31/2020 | 793 | 148 | 110 | 175 | N/A |
| 12/31/2019 | 785 | 155 | 101 | 172 | N/A |
| 9/30/2019 | 770 | 146 | 90 | 162 | N/A |
| 6/30/2019 | 743 | 143 | 82 | 158 | N/A |
| 3/31/2019 | 722 | 150 | 93 | 169 | N/A |
| 12/31/2018 | 713 | 156 | 122 | 182 | N/A |
| 9/30/2018 | 693 | 144 | 126 | 182 | N/A |
| 6/30/2018 | 676 | 134 | 112 | 165 | N/A |
| 3/31/2018 | 655 | 118 | 106 | 158 | N/A |
| 12/31/2017 | 636 | 107 | N/A | 159 | N/A |
| 9/30/2017 | 612 | 107 | N/A | 166 | N/A |
| 6/30/2017 | 595 | 108 | N/A | 174 | N/A |
| 3/31/2017 | 581 | 105 | N/A | 171 | N/A |
| 12/31/2016 | 564 | 104 | N/A | 148 | N/A |
| 9/30/2016 | 553 | 118 | N/A | 166 | N/A |
| 6/30/2016 | 554 | 118 | N/A | 153 | N/A |
| 3/31/2016 | 548 | 116 | N/A | 143 | N/A |
| 12/31/2015 | 537 | 113 | N/A | 124 | N/A |
| 9/30/2015 | 518 | 103 | N/A | 80 | N/A |
| 6/30/2015 | 499 | 99 | N/A | 85 | N/A |
| 3/31/2015 | 481 | 96 | N/A | 85 | N/A |
| 12/31/2014 | 467 | 92 | N/A | 79 | N/A |
| 9/30/2014 | 454 | 86 | N/A | 110 | N/A |
| 6/30/2014 | 443 | 83 | N/A | 108 | N/A |
| 3/31/2014 | 436 | 70 | N/A | 104 | N/A |
| 12/31/2013 | 427 | 69 | N/A | 93 | N/A |
| 9/30/2013 | 420 | 68 | N/A | 86 | N/A |
| 6/30/2013 | 407 | 65 | N/A | 69 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GMED's forecast earnings growth (40.9% per year) is above the savings rate (2.4%).
Earnings vs Market: GMED's earnings (40.9% per year) are forecast to grow faster than the US market (14.6% per year).
High Growth Earnings: GMED's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GMED's revenue (11.2% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: GMED's revenue (11.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GMED's Return on Equity is forecast to be low in 3 years time (10.2%).